A total of 200,000 doses of the vaccine developed by CanSino Biologics Inc from China arrived at Kuala Lumpur International Airport (KLIA) here at about 8.45am via a Malaysia Airlines flight.

The Covid-19 Immunisation Task Force (CITF) said the 200,000 doses of the “finished product” vaccine were part of the 3.5 million doses of CanSino vaccine that had been ordered by Malaysia for delivery to the country in stages.

“This vaccine supply will further intensify PICK especially in low-access areas, and will help Malaysia achieve herd immunity as targeted in the national recovery plan within the set time,” it said in a statement.

Present to receive the vaccine at KLIA were science, technology and innovation ministry secretary-general Siti Hamisah Tapsir and health ministry secretary-general Mohd Shafiq Abdullah.

Solution Biologics Sdn Bhd (SOLBIO), a subsidiary of Solution Group Bhd, on July 30 signed finished product and bulk product agreements with CanSino Biologics Inc for the supply of the Recombinant Ad5-nCoV vaccine.

Both agreements allowed SOLBIO to supply 3.5 million doses of vaccine to the health ministry and accept additional orders from the ministry, state governments, the private sector and other Asean countries.

The CanSino vaccine was given conditional approval for emergency use in Malaysia by the Drug Control Authority (DCA) on June 15.

On June 17, then coordinating minister for PICK Khairy Jamaluddin was reported to have said that the CanSino vaccine would be offered to states with hard-to-access rural areas such as Pahang, Sabah and Sarawak.

With the single-dose vaccine, health workers will not have to enter the rural areas for a second time to complete the vaccination to recipients, he said.

Currently, Malaysia uses the two-dose vaccines of the Pfizer-BioNTech, Sinovac and AstraZeneca types. The CanSino single-dose vaccine will be the latest to be used under PICK.

CLICK HERE FOR THE LATEST DATA ON THE COVID-19 SITUATION IN MALAYSIA